Pfizer Inc. (NYSE:PFE), IBM team up in research to combat Parkinson’s disease
Pfizer Inc. (NYSE:PFE) doesn’t dwell on disappointments. After ending its pursuit of Allergan PLC (NYSE:AGN) on a disappointing note, Pfizer is looking ahead. The company recently announced a partnership with the International Business Machines Corp. (NYSE:IBM) that would see it benefit from the latter’s cognitive computing technology in future clinical trials.
Pfizer Inc. (NYSE:PFE) and IBM have come together to jointly launch a research initiative focused on Parkinson’s disease. Their target is to understand more about the neurological condition so as to improve the kind of care that patients afflicted with the condition receive. The collaboration is also expected to help accelerate clinical trials for new medicines to combat Parkinson’s disease.
A house enriched with sensors
The joint research facility will be located in Yorktown Heights, NY, near IBM’s Watson Research Center. The facility will be designed in the form of a regular house, but will be equipped with multiple sensors to collect data on various elements of Parkinson’s disease. The idea of equipping the research house with sensors will be to facilitate real-time collection of data about how patients are responding to treatments and the progression of their conditions. Some of the data that will be fetched from Parkinson’s disease patients in the research house include motor function, cognition and daily activities such as eating and dressing.
Pfizer Inc. (NYSE:PFE) and IBM said they will include control subjects in the research house.
Leveraging IBM’s cognitive computing technology, the researchers at the joint Parkinson’s disease research center will be able to understand the unique link between the symptoms and timing or dosing of medicine. That should help in developing the right dose of a particular drug for the patients. That way, Pfizer can be able to speed up its clinical trials of Parkinson’s disease drug candidates.
Pfizer Inc. (NYSE:PFE) has a Parkinson’s disease targeted experimental drug called PF-06649751, which is expected to enter Phase 3 trial in 2019.
Although the initial focus is on Parkinson’s disease, Pfizer Inc. (NYSE:PFE) is hopping that it would in the future expand the program with IBM to include research into other devastating conditions such as Alzheimer’s and Huntington’s diseases.
Latest posts by Neha Gupta (see all)
- Is Facebook Inc (NASDAQ:FB) Winning Or Losing In Virtual Reality Space? - May 27, 2016 07:35 AM PDT
- No Growth In Costco Wholesale Corporation (NASDAQ:COST)’s 3Q Comps Explained - May 27, 2016 07:34 AM PDT
- How Will International Business Machines Corp. (NYSE:IBM)’s Big Data University Help? - May 27, 2016 07:33 AM PDT